Status:
COMPLETED
Immune Response After Stem Cell Transplant in HIV-Positive Patients With Hematologic Cancer
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)
Conditions:
Hematopoietic and Lymphoid Cell Neoplasm
HIV Infection
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
This phase II trial studies the immune response after stem cell transplant in human immunodeficiency virus (HIV)-positive patients with hematologic cancer (blood cancer). Studying samples of blood fro...
Detailed Description
PRIMARY OBJECTIVES: I. Examine the development of donor-derived HIV-1-specific immune response following hematopoietic cell transplant (HCT) for treatment of hematologic malignancy in HIV+ patients. ...
Eligibility Criteria
Inclusion
- HIV positive
- Treatment with highly active antiretroviral therapy (HAART) for at least 1 month
- Viral load has decreased by \>= 1.5 logs or viral load \< 5000 copies/ml plasma on HAART therapy
- Hematologic malignancy associated with a poor prognosis or other diagnosis for which hematopoietic cell therapy (allogeneic or autologous, including gene therapy) is indicated
- Approval for allogenic regimen given at Patient Care Conference
- DONOR: Autologous or allogeneic gene modified cells allowed
Exclusion
- A medical history of noncompliance with HAART or medical therapy
- Inability to provide informed consent
- DONOR: Allogeneic donors must not have HIV infection
Key Trial Info
Start Date :
December 17 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 17 2017
Estimated Enrollment :
9 Patients enrolled
Trial Details
Trial ID
NCT00968630
Start Date
December 17 2009
End Date
March 17 2017
Last Update
May 24 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109